Log in

NASDAQ:CVETCovetrus Stock Price, Forecast & News

$8.40
+0.89 (+11.85 %)
(As of 04/10/2020 06:42 AM ET)
Add
Compare
Today's Range
$7.62
Now: $8.40
$8.88
50-Day Range
$5.64
MA: $8.94
$12.95
52-Week Range
$4.05
Now: $8.40
$33.50
Volume1.37 million shs
Average Volume2.11 million shs
Market Capitalization$938.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:CVET
CUSIPN/A
CIKN/A
Phone888-280-2221

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.98 billion
Cash Flow$12.00 per share
Book Value$11.20 per share

Profitability

Net Income$-1,019,000,000.00

Miscellaneous

Employees5,500
Market Cap$938.36 million
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.


Covetrus (NASDAQ:CVET) Frequently Asked Questions

How has Covetrus' stock been impacted by COVID-19 (Coronavirus)?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CVET shares have decreased by 7.1% and is now trading at $8.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Covetrus?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Covetrus.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Covetrus.

How were Covetrus' earnings last quarter?

Covetrus Inc (NASDAQ:CVET) announced its quarterly earnings results on Tuesday, March, 3rd. The company reported $0.18 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.12 by $0.06. The company earned $1.01 billion during the quarter, compared to analyst estimates of $985.29 million. Covetrus had a negative net margin of 24.30% and a positive return on equity of 3.70%. Covetrus's quarterly revenue was up 11.6% on a year-over-year basis. View Covetrus' earnings history.

What guidance has Covetrus issued on next quarter's earnings?

Covetrus issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.025-4.125 billion, compared to the consensus revenue estimate of $4.14 billion.

What price target have analysts set for CVET?

6 brokers have issued 1 year price targets for Covetrus' stock. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' stock price to reach $15.75 in the next twelve months. This suggests a possible upside of 87.5% from the stock's current price. View analysts' price targets for Covetrus.

Has Covetrus been receiving favorable news coverage?

News articles about CVET stock have trended very negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Covetrus earned a news impact score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutCovetrus.

Are investors shorting Covetrus?

Covetrus saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 19,820,000 shares, an increase of 12.4% from the February 13th total of 17,630,000 shares. Based on an average trading volume of 1,540,000 shares, the short-interest ratio is currently 12.9 days. Approximately 20.5% of the shares of the stock are sold short. View Covetrus' Current Options Chain.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Uber Technologies (UBER), Century Aluminum (CENX), IDEXX Laboratories (IDXX), RealReal (REAL), SVMK (SVMK), Chewy (CHWY), Evolent Health (EVH), Tapestry (TPR), Verizon Communications (VZ) and Advanced Micro Devices (AMD).

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Benjamin J. Shaw, President, Chief Executive Officer & Director
  • Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
  • Matthew Leonard, Executive VP & President-North America
  • Jim Young, Chief Human Resources Officer & Senior VP
  • Erin Powers Brennan, Secretary, Senior Vice President & General Counsel

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Erin Powers Brennan and Timothy Ludlow. View institutional ownership trends for Covetrus.

Which institutional investors are buying Covetrus stock?

CVET stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan. View insider buying and selling activity for Covetrus.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $8.40.

How big of a company is Covetrus?

Covetrus has a market capitalization of $938.36 million and generates $3.98 billion in revenue each year. The company earns $-1,019,000,000.00 in net income (profit) each year or $0.79 on an earnings per share basis. Covetrus employs 5,500 workers across the globe. View additional information about Covetrus.

What is Covetrus' official website?

The official website for Covetrus is http://www.henryscheinvet.com/.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Featured Article: What is Blockchain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel